/
BHST
$2.79+$0.02 (+0.72%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$62.8M
23M shares
52-week range
$2.75 – $12.80
0% from low
Exchange
NASDAQ
CS
Borrow rate
1.04%
Moderate
Price (6 mo)
Loading chart…
Change$-2.96
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $218.0K | $396.0K | $2.1M | $5.5M | $12.7M | $25.2M | $34.5M |
| Cost of revenue | $0 | $189.0K | $258.0K | $1.4M | $4.3M | $7.0M | $11.2M | $14.0M |
| Gross profit | $0 | $29.0K | $138.0K | $670.0K | $1.2M | $5.6M | $13.9M | $20.5M |
| Gross margin | — | 13.3% | 34.8% | 31.9% | 22.2% | 44.5% | 55.4% | 59.3% |
| R&D | $0 | $1.3M | $1.3M | $4.1M | $2.3M | $3.4M | $4.8M | $5.3M |
| Operating income | −$4.4M | −$2.3M | −$6.2M | −$8.5M | −$10.6M | −$10.0M | −$7.0M | −$5.6M |
| EBITDA | $0 | −$2.0M | −$5.8M | −$8.6M | −$9.1M | −$9.8M | −$9.7M | −$6.7M |
| Net income | $0 | −$5.3M | −$6.6M | −$9.8M | −$11.2M | −$12.6M | −$12.9M | −$11.1M |
| Net margin | — | -2435.8% | -1662.6% | -467.5% | -204.4% | -99.1% | -51.3% | -32.3% |
| EPS (diluted) | -2.34 | -1.75 | -0.70 | -0.70 | -0.70 | -0.93 | -0.80 | -0.60 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $43M | $-0.40 | $-0.40–$-0.38 | 3 |
| 2027 | $59M | $-0.16 | $-0.20–$-0.13 | 3 |
| 2028 | $96M | $0.41 | $0.38–$0.43 | 1 |
| 2029 | $129M | $0.83 | $0.78–$0.88 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
BioHarvest Sciences Inc. Common Stock
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
www.bioharvest.com- Employees
- 89
- IPO / List date
- Feb 11, 2019
Held by traders on TradeandTell
No one on the platform currently holds BHST.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in BHST as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BHST yet.
